The methods described herein allow for the classification of patients into groups for receiving optimized radiation treatment based on patient specific biomarker signature. The biomarker signature includes markers that have been shown to correlate with TGF-B expression and to be associated with tumor aggressiveness, radioresistance and poor prognosis. The markers play a key role in the epithelial-mesenchymal transition. The methods described herein provide the dual benefits of anti-tumor efficacy plus normal tissue protection when combining TGF-B inhibitors with ionizing radiation to treat cancer patients.

Provided herein, in some embodiments, are methods and compositions for detecting differentially expressed genes in a sample obtained from a subject having or at risk for preeclampsia.

The present invention provides a tumor blood marker and a use thereof. Specifically, the present invention provides a use of a reagent, which is used to detect GAPDH in a blood sample, in a preparation of a detecting composition for tumor screening, risk evaluation of tumor development in subjects, distinction of tumor progression stages, identification of therapeutic efficacy of tumor and/or risk analysis of tumor progression. The present invention also provides a kit and a method for detecting GAPDH concentrations in blood samples.

[Problem to be Solved] To provide a fluorescent probe for ALDH3A1 detection that can be used in flow cytometry adaptable to live cells.

[Means of Resolution] A compound represented by general formula (I) or a salt thereof, wherein the compound or salt thereof has a retention time on an HPLC chromatogram measured under the following conditions of longer than 6.9 minutes when said compound is in aldehyde form and of 6.9 minutes or less when said compound is in carboxylic acid form.

Methods and compositions are provided for treating endometriosis in an individual, and the pain associated with endometriosis. Aspects of the methods include administering to the individual an agent that promotes ALDH activity.

A detection system for determining pyruvate dehydrogenase (PDH) levels in a bodily sample includes at least one reaction solution for generating NAD.sup.+ upon combination with PDH in the bodily sample, the reaction solution including pyruvate and NADH and a biosensor for determining the level of generated NAD.sup.+.

Lateral flow devices, methods and kits for performing lateral flow western blot assays are provided.

The present invention provides a tumor blood marker and a use thereof. Specifically, the present invention provides a use of a reagent, which is used to detect GAPDH in a blood sample, in a preparation of a detecting composition for tumor screening, risk evaluation of tumor development in subjects, distinction of tumor progression stages, identification of therapeutic efficacy of tumor and/or risk analysis of tumor progression. The present invention also provides a kit and a method for detecting GAPDH concentrations in blood samples.

Methods are disclosed for producing populations of cardiomyocytes from pluripotent stem cells. Populations may be enriched for either atrial or ventricular cardiomyocytes and the resulting ventricular population may be essentially free of pacemaker cells. The method includes incubating pluripotent stem cells in a suitable medium with a BMP component, and an activin component, the amounts of activin may be varied to enrich for either atrial or ventricular cardiomyocytes. The enriched populations, as well as methods of using the same to treat patients in need of cardiac repair are disclosed.

A detection system for determining pyruvate dehydrogenase (PDH) levels in a bodily sample includes at least one reaction solution for generating NAD.sup.+ upon combination with PDH in the bodily sample, the reaction solution including pyruvate and NADH and a biosensor for determining the level of generated NAD.sup.+.